arrow_back Back to App

Crisis Preparedness: US Production and National Preparedness Commission

This act aims to enhance the United States' readiness for future crises, such as pandemics. It mandates that key medical and emergency products be manufactured in the USA. It also establishes a special commission to review the COVID-19 response and prepare the nation for future threats, ensuring greater safety and availability of essential goods for citizens.
Key points
US Production Requirement: Key medical and emergency products essential during crises will be required to be manufactured in the United States starting in 2026, aiming to ensure their availability.
New Preparedness Commission: An independent commission will be established to examine the nation's response to the COVID-19 pandemic and provide recommendations for better handling future disasters.
Tax Incentives for Manufacturers: Companies producing pharmaceuticals and medical devices in the US may receive special tax allowances, encouraging investment in domestic manufacturing.
Consequences for States: States failing to implement the commission's preparedness recommendations by 2026 may lose federal emergency preparedness funding.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3584
Sponsor: Rep. Fitzpatrick, Brian K. [R-PA-1]
Process start date: 2021-05-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Made in America Emergency Preparedness Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3584.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-05-28.

What are the main provisions?

Key points include:

  • US Production Requirement: Key medical and emergency products essential during crises will be required to be manufactured in the United States starting in 2026, aiming to ensure their availability.
  • New Preparedness Commission: An independent commission will be established to examine the nation's response to the COVID-19 pandemic and provide recommendations for better handling future disasters.
  • Tax Incentives for Manufacturers: Companies producing pharmaceuticals and medical devices in the US may receive special tax allowances, encouraging investment in domestic manufacturing.
  • Consequences for States: States failing to implement the commission's preparedness recommendations by 2026 may lose federal emergency preparedness funding.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Fitzpatrick, Brian K. [R-PA-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Economic Development, Public Buildings, and Emergency Management.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Security Economy